| Old Articles: <Older 1571-1580 Newer> |
|---|
 |
Fast Company
December 2004
Paul B. Brown |
What I Know Now Myrtle S. Potter, a top exec at Genentech, explains how to pare down, focus, and move forward.   |
The Motley Fool
November 30, 2004
Brian Gorman |
Glaxo Targeted for Kids' Trials Criticism of Glaxo could benefit investors in the long run: Although these companies will continue to evolve, their role as dominant players in drug development seems secure. Those investors willing to dip a toe in now could reap rich rewards. |
The Motley Fool
November 30, 2004
Rich Smith |
Merck Execs Circle the Wagons Shareholder anger is elicited by a filing that Merck made with the Securities and Exchange Commission, announcing that in anticipation of a possible hostile takeover, its executives are taking all possible measures to protect... themselves. |
The Motley Fool
November 30, 2004
Rich Smith |
Breaking Rules and Saving Lives Cord blood offers an ethical means of using stem cells to heal illness. While two top companies in the field are private, over the counter traded Cryo-Cell lost as much money as it collected in revenues last year. |
The Motley Fool
November 30, 2004
Charly Travers |
Picking Biotech's Winners Doing well as a biotech investor comes as much from avoiding the losers as picking the winners. A quick screen for making winning investment picks. |
The Motley Fool
November 29, 2004
Charly Travers |
Genta Is Worth Nada Latest trial failure leaves the pharmaceutical company with few options. Without Genasense, Genta is essentially a shell of a company with no means of creating value for shareholders. |
The Motley Fool
November 29, 2004
Brian Gorman |
Glass Half Full for Bayer Bayer is battling drug recall demons, but the company's positives seem to outweigh its negatives. The German drug and chemical giant posted a net profit of $42 million, reversing a massive loss recorded in the same period last year. |
BusinessWeek
December 6, 2004
Kathleen Kerwin |
Knees And Hips -- And Now What? Stryker may need more than artificial joints. Its CEO-to-be is betting on biotech. |
BusinessWeek
December 6, 2004
Catherine Arnst |
Cord Blood To The Rescue A study in the Nov. 25 issue of The New England Journal of Medicine confirms that stem cells in blood extracted from the umbilical cords of newborns can help leukemia patients |
BusinessWeek
December 6, 2004
Gene G. Marcial |
Boston Scientific: Anemic -- For Now Boston Scientific is far from robust -- since its summer recall of 100,000 coronary stents and since its lowered fourth-quarter profit forecast. Analysts quickly cut estimates, driving shares down from 46 in May to 33.36 on Nov. 23. |
| <Older 1571-1580 Newer> Return to current articles. |
